New Publication of Peer-Reviewed Study in NeurologyIndependently Verifies Nymox AD7C Test.

Business Editors & Medical Writers

MAYWOOD, N.J.--(BUSINESS WIRE)--April 25, 2000

A new peer-reviewed publication in the April 2000 issue of Neurology has again independently verified the utility of Nymox's AD7C(TM) test as an aid to diagnosis in Alzheimer's disease (Neurology

Neurology is the official journal of the American Academy of Neurology. The clinical researchers in this independent study, led by Dr. Philipp Kahle of Stanford, were from the Departments of Neurobiology, Psychiatry, Behavioral Sciences, and Neurosurgery at Stanford, the Parkinson's Institute of Sunnyvale California, and the Department of Psychiatry of Ludwig-Maximilians-University School of Medicine in Munich, Germany.

The study found that AD7C(TM) was significantly elevated in patients with Alzheimer's disease compared to controls. AD7C levels also correlated significantly with the severity of dementia symptoms. The article stated, "levels of AD7C-NTP correlated with severity of dementia as assessed by MMSE (Mini-Mental State Evaluation), consistent with the previous study using the Blessed dementia scale." (NTP is an abbreviation for neural thread protein.)

Dr. Michael Munzar, Medical Director of Nymox, said, "AD7C has repeatedly been shown in numerous independent studies to be an early, accurate, and useful biochemical marker for Alzheimer's disease. Importantly, in the new publication in Neurology AD7C has again been shown to be the only marker shown to correlate with the severity of memory loss in AD. This clearly supports its clinical utility as an aid to diagnosis in Alzheimer's disease."

Nymox Pharmaceutical Corporation pioneers in the research and development of products for the diagnosis and treatment of Alzheimer's disease, an affliction of more than 20 million people around the world. Nymox offers the world's only accurate, non-invasive test to aid in the diagnosis of the disease, and is developing proprietary spheron-based drug therapies that could lead to effective treatment of Alzheimer's disease. Nymox recently acquired a majority interest in Serex, Inc., a New Jersey corporation with proprietary tests under development in the fields of geriatric, cardiovascular, metabolic and musculoskeletal disease. Nymox is also developing a new class of antibacterial agents for the treatment of urinary tract and other bacterial infections in humans which have proved highly resistant to conventional antibiotic treatments and for the treatment of E. coli 0157:H7 bacterial contamination in hamburger meat and other food and drink products. Nymox Pharmaceutical Corporation is headquartered in Montreal, with facilities in Kensington, MD and Maywood, N.J. Its stock is traded on NASDAQ with the symbol NYMX. More information is available at http://www.nymox.com.

This press release contains certain forward-looking statements as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.